Loading stock data…
VALN
$5.35-0.03 (-0.56%)
Market ClosedLast close May 1
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Valneva SE in the Healthcare sector is trading at $5.35. The stock is currently near its 52-week low of $5.15, remaining 40.6% below its 200-day moving average. Technical signals show oversold RSI of 26 and bullish MACD crossover, explaining why VALN maintains its current current market pressure. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 26) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$5.35
Potential Upside
5%
Whystock Fair Value$5.62
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus4 analysts
Buy
Mean target$12.22+128.5%
Range$4.90 – $18.00
Fundamentals
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$471.53M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.53
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-108.50%
Volume
Today's trading volume
16,760
Recent News
Guggenheim Cuts PT on Valneva SE (VALN) to $11 From $13
Valneva SE (NASDAQ:VALN) is one of the most undervalued biotech stocks to buy right now. Guggenheim cut the price target on Valneva SE (NASDAQ:VALN) to $11 from $13 on April 16, reiterating a Buy rating on the shares. The firm adjusted estimates on the stock as part of a fiscal Q1 earnings preview for the commercial stage […]
Jefferies Reiterates Buy Rating on Valneva (VALN) After Phase 3 Data
Valneva SE (NASDAQ:VALN) is one of the 8 Most Oversold Strong Buy-Rated Stocks to Invest In. On March 23, 2026, Jefferies reiterated a Buy rating and $15 price target on Valneva SE (NASDAQ:VALN) following topline results from the Phase 3 VALOR trial of its Lyme disease vaccine candidate PF-07307405. Jefferies said that the stock reaction […]
Will Pfizer’s Lyme disease gamble pay off or set the space back?
As the disease spreads into new regions, the urgency for prevention is growing.
Pfizer (PFE) – Among the 15 Large Cap Stocks with Highest Dividends
Pfizer Inc. (NYSE:PFE) is included among the 15 Large Cap Stocks with Highest Dividends. Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company’s global portfolio includes medicines and vaccines, as well as many of the world’s best-known consumer health care products. Pfizer Inc. (NYSE:PFE) […]
Should Pfizer’s (PFE) New Lyme Vaccine and Oncology Wins Reshape Its Post‑COVID Pipeline Story?
In March 2026, Pfizer and partner Valneva reported that their investigational 6‑valent OspA-based Lyme disease vaccine achieved roughly three‑quarters efficacy in a Phase 3 trial, while separate late‑stage studies in prostate and breast cancer also met key endpoints with TALZENNA and atirmociclib. Together, these trial wins highlight how Pfizer’s late‑stage pipeline is broadening beyond COVID-era products into vaccines and oncology programs that could reshape its future product mix. We’ll...